{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Akebia Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"AKBA"},"Address":{"label":"Address","value":"245 FIRST STREET SUITE 1100, CAMBRIDGE, Massachusetts, 2142, United States"},"Phone":{"label":"Phone","value":"+1 617 871-2098"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.akebia.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"John P. Butler","title":"President, Chief Executive Officer &amp; Director"},{"name":"Michael Rabinowitz","title":"Vice President-Research"},{"name":"Michel Dahan","title":"Chief Operating Officer &amp; Senior Vice President"},{"name":"Steven K. Burke","title":"Chief Medical Officer &amp; Senior Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}